Identification, Isolation, and Functional Assay of Regulatory T Cells

Immunological Investigations

Volumn 45, Issue 7, 2016, Pages 584-602

  Azimi, Maryam ^a   Aslani, Saeed ^a   Mortezagholi, Sahar ^b   Salek, Amir ^c   Javan, Mohammad Reza ^d   Rezaiemanesh, Alireza ^a   Ghaedi, Mojgan ^e   Gholamzad, Mehrdad ^c   Salehi, Eisa ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TARBIAT MODARES UNIVERSITY   (Iran)

^d ZABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cell isolation; functional assay; regulatory T cells; therapeutic tool

Indexed keywords

INTERLEUKIN 2 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; CD4 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR ALPHA;

ALPHA CHAIN; CD4+ CD25+ T LYMPHOCYTE; CELL DIVISION; CELL ISOLATION; CELL PROLIFERATION; CELL SELECTION; COMPARATIVE STUDY; DNA REPLICATION; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; ANIMAL; IMMUNOTHERAPY; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD4; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; IMMUNOASSAY; IMMUNOTHERAPY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84988727191     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.1080/08820139.2016.1193869     Document Type: Review

References (128)

1. J.Armitage Richard, W.C.FanslowWilliam C, L.StrockbineLaura, et al. (1992). Molecular and biological characterization of a murine ligand for CD40. Nature, 357 (6373), 80–82.
2. A.BeccaAsquith, C.DebacqChristophe, A.FlorinsArnaud, et al. (2006). Quantifying lymphocyte kinetics in vivo using carboxyfluorescein diacetate succinimidyl ester. Proc R Soc London, B, 273 (1590), 1165–1171.
3. B.-A.ClareBaecher-Allan, J.A.BrownJulia A, G.J.FreemanGordon J, D.A.HaflerDavid A. (2001). CD4+ CD25high regulatory cells in human peripheral blood. J Immunol, 167 (3), 1245–1253.
4. B.SamikBasu, T.GolovinaTatiana, T.MikheevaTatiana, et al. (2008). Cutting edge:Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol, 180 (9), 5794–5798.
5. B.ManuelaBattaglia, A.StabiliniAngela, B.MigliavaccaBarbara, et al. (2006). Rapamycin promotes expansion of functional CD4+ CD25+ FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol, 177 (12), 8338–8347.
6. B.ManuelaBattaglia, A.StabiliniAngela, M.-G.RoncaroloMaria-Grazia. (2005). Rapamycin selectively expands CD4+ CD25+ FoxP3+ regulatory T cells. Blood, 105 (12), 4743–4748.
7. B.JagadeeshBayry, J.-F.GautierJean-François. (2016). Regulatory T Cell Immunotherapy for Type 1 Diabetes:A Step Closer to Success? Cell Metab, 23 (2), 231–233.
8. J.Benson Micah, K.Pino-LagosKarina, M.RosemblattMario, R.J.NoelleRandolph J. (2007). All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med, 204 (8), 1765–1774.
9. W.Bergler, G.Petroianu, A.Schadel (1993). Feasibility of proliferation studies using the BrdU and MTT assays with a head and neck carcinoma cell line. ORL, 55 (4), 230–235.
10. J.A.Bluestone, A.K.Abbas (2003). Natural versus adaptive regulatory T cells. Nat Rev Immunol, 3 (3), 253–7. doi:10.1038/nri1032.
11. B.GennadyBocharov, T.LuzyaninaTatyana, J.CupovicJovana, B.LudewigBurkhard. (2013). Asymmetry of cell division in CFSE-based lymphocyte proliferation analysis. Frontiers Immunol, 4, 1–7.
12. B.GiovannaBorsellino, M.KleinewietfeldMarkus, D.D.MitriDiletta Di, et al. (2007). Expression of ectonucleotidase CD39 by Foxp3+ Treg cells:hydrolysis of extracellular ATP and immune suppression. Blood, 110 (4), 1225–1232.
13. B.ToddBrusko, J.BluestoneJeffrey. (2008). Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation. Eur J Immunol, 38 (4), 931–934.
14. M.Brusko Todd, M.A.HulmeMaigan A, C.B.MyhrCourtney B, et al. (2007). Assessing the in vitro suppressive capacity of regulatory T cells. Immunol Invest, 36 (5–6), 607–628.
15. M.Brusko Todd, A.L.PutnamAmy L, J.A.BluestoneJeffrey A. (2008). Human regulatory T cells:role in autoimmune disease and therapeutic opportunities. Immunol Rev, 223 (1), 371–390.
16. B.Canavan James, B.AfzaliBehdad, G.M.LordGraham M, G.LombardiGiovanna. (2013). Assessment of regulatory T-cell function in forthcoming clinical trials of cell therapy. Expert Rev Mol Diagn, 13 (1), 5–7.
17. B.Canavan James, B.AfzaliBehdad, C.ScottàCristiano, et al. (2012). A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. Blood, 119 (8), e57–e66.
18. C.ArnoldoCaruso, S.Licenziati, M.CorulliMaria, et al. (1997). Flow cytometric analysis of activation markers on stimulated T-cells and their correlation with cell proliferation. Cytometry, 27 (1), 71–76.
19. C.CristinaCellerai, A.HarariAlexandre, F.VallelianFlorence, et al. (2007). Functional and phenotypic characterizationof tetanus toxoid‐specific human CD4+ T cellsfollowing re‐immunization. Eur J Immunol, 37 (4), 1129–1138.
20. P.K.Chattopadhyay, Pratip K, Y.JoanneYu, M.RoedererMario. (2005). A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nature Med, 11 (10), 1113–1117.
21. T.Chodon, Thinle, R.C.KoyaRichard C, K.OdunsiKunle. (2015). Active immunotherapy of cancer. Immunol Invest, 44 (8), 817–836.
22. C.MaciejCiebiada, K.KasztalskaKarolina, M.Gorska-CiebiadaMałgorzata, et al. 2013. Basic research:Expression of IL-7 receptor in human peripheral regulatory T cells. Arch Med Sci, 9, 555–560.
23. C.Clarke, J.Titley, S.Davies, M.J.O’Hare (1994). An immunomagnetic separation method using superparamagnetic (MACS) beads for large-scale purification of human mammary luminal and myoepithelial cells. Epithelial Cell Biol, 3 (1), 38–46.
24. J.A.Coenen Jeroen, H.J.P.M.KoenenHans JPM, E.van RijssenEsther, et al. (2006). Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+ CD25+ regulatory T cells. Blood, 107 (3), 1018–1023.
25. W.Collison Lauren, D.A.A.VignaliDario AA. (2011). In vitro Treg suppression assays. In R.T.CellsRegulatory T, 21–37. Springer.
26. R.Craston, M.Koh, A.Mc Dermott, et al. (1997). Temporal dynamics of CD69 expression on lymphoid cells. J Immunol Methods, 209 (1), 37–45.
27. C.de Lafaille MACurotto, J.J.Lafaille (2009). Natural and adaptive foxp3+ regulatory T cells:more of the same or a division of labor? Immunity, 30 (5), 626–35. doi:10.1016/j.immuni.2009.05.002.
28. D.S., DwyerDeaglio S K.M., Gao W, et al. (2007). Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med, 204 (6), 1257–1265.
29. E.A.De Wynter, Coutinho L.H., Pei X, et al. (1995). Comparison of purity and enrichment of CD34+ cells from bone marrow, umbilical cord and peripheral blood (primed for apheresis) using five separation systems. Stem Cells, 13 (5), 524–532.
30. D.DetlefDieckmann, H.PlottnerHeidi, S.BerchtoldSusanne, et al. (2001). Ex vivo isolation and characterization of CD4+ CD25+ T cells with regulatory properties from human blood. J Exp Med, 193 (11), 1303–1310.
31. J.Doolittle David, S.C.McKarnsSusan C, P.H.AyresPaul H, D.W.BombickDavid W. (1991). Technology Review:Molecular Approaches for Quantifying DNA Synthesis and Cell Proliferation During Rodent Bioassays. Toxicol Methods, 1 (4), 215–230.
32. A.Duque, P.Rakic (2011). Different effects of bromodeoxyuridine and [3H]thymidine incorporation into DNA on cell proliferation, position, and fate. J Neurosci, 31 (42), 15205–17. doi:10.1523/jneurosci.3092-11.2011.
33. K.E.Earle, Q.Tang, X.Zhou, (2005). In vitro expanded human CD4+ CD25+ regulatory T cells suppress effector T cell proliferation. Clinical Immunol, 115 (1), 3–9.
34. E.JohanneseGerdes, H.LemkeHilmar, H.BaischHeinz, et al. (1984). Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol, 133 (4), 1710–1715.
35. V.Fleskens, van Boxtel R. (2014). Forkhead Box P family members at the crossroad between tolerance and immunity:a balancing act. Int Rev Imm, 33, 94–109.
36. D.Fontenot Jason, M.A.GavinMarc A, A.Y.RudenskyAlexander Y. (2003). Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nature Immunol, 4 (4), 330–336.
37. A.P.Franken Nicolaas, H.M.RodermondHans M, J.StapJan, et al. (2006). Clonogenic assay of cells in vitro. Nature Protocols, 1 (5), 2315–2319.
38. F.MarcoFrentsch, O.ArbachOlga, D.KirchhoffDennis, et al. (2005). Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nature Med, 11 (10), 1118–1124.
39. G.LeonaGabryšová, J.R.ChristensenJillian R, W.XuemeiWu, et al. (2011). Integrated T‐cell receptor and costimulatory signals determine TGF‐β‐dependent differentiation and maintenance of Foxp3+ regulatory T cells. Eur J Immunol, 41 (5), 1242–1248.
40. S.Ganapathy-Kanniappan, J.F.Geschwind, R.Kunjithapatham, et al. (2010). The pyruvic acid analog 3-bromopyruvate interferes with the tetrazolium reagent MTS in the evaluation of cytotoxicity. Assay Drug Dev Technol, 8 (2), 258–62. doi:10.1089/adt.2009.0226.
41. A.Garcia Santana Carlos, J.W.TungJames W, S.GulnikSergei. (2014). Human treg cells are characterized by low/negative CD6 expression. Cytometry Part A, 85 (10), 901–908.
42. L.Geiger Terrence, S.TauroSharyn. 2012. Nature and nurture in Foxp3+ regulatory T cell development, stability, and function. Human Immunol, 73 (3), 232–239.
43. I.Gerashchenko Bogdan (2011). Choosing a cell sorting option to study the fate of bystander cells:FACS or MACS? Cytometry Part A, 79 (3), 179–180.
44. J.Gerdes (1990). Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Seminars in cancer biology.
45. R.Godfrey Wayne, G.Ge Ying, D.J.SpodenDarrin J, et al. (2004). In vitro–expanded human CD4+ CD25+ T-regulatory cells can markedly inhibit allogeneic dendritic cell–stimulated MLR cultures. Blood, 104 (2), 453–461.
46. N.Golovina Tatiana, T.MikheevaTatiana, T.M.BruskoTodd M, et al. (2011). Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PloS One, 6 (1), e15868–e15868.
47. N.Golovina Tatiana, T.MikheevaTatiana, M.M.SuhoskiMegan M, et al. (2008). CD28 costimulation is essential for human T regulatory expansion and function. J Immunol, 181 (4), 2855–2868.
48. C.R.Grant, R.Liberal, G.Mieli-Vergani, D.Vergani, M.S.Longhi (2015). Regulatory T-cells in autoimmune diseases:challenges, controversies and–yet–unanswered questions. Autoimmun Rev, 14 (2), 105–16. doi:10.1016/j.autrev.2014.10.012.
49. L.GreenLouisa. (2014). Development of an anti-CD2/CD3/CD28 bead-based T-cell proliferation assay. Biosci Horiz, 7, hzu012.
50. G.MaudeGuillot‐Delost, M.CheraiMustapha, Y.HamelYamina, et al. (2008). Clinical‐grade preparation of human natural regulatory T‐cells encoding the thymidine kinase suicide gene as a safety gene. J Gene Med, 10 (8), 834–846.
51. D.J.Hartigan-O’ConnorDennis J, C.PoonChungkee, E.SinclairElizabeth, J.M.McCuneJoseph M. (2007) Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods, 319 (1–2), 41–52. doi: http://dx.doi.org/10.1016/j.jim.2006.10.008.
52. E.Himmel Megan, Y.YaoYu, P.C.OrbanPaul C, et al. (2012). Regulatory T‐cell therapy for inflammatory bowel disease:more questions than answers. Immunol, 136 (2), 115–122.
53. H.PetraHoffmann, R.EderRuediger, T.J.BoeldTina J, et al. (2006). Only the CD45RA+ subpopulation of CD4+ CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood, 108 (13), 4260–4267.
54. H.PetraHoffmann, R.EderRuediger, L.A.Kunz-SchughartLeoni A, et al. (2004). Large-scale in vitro expansion of polyclonal human CD4+ CD25high regulatory T cells. Blood, 104 (3), 895–903.
55. H.ShoheiHori, T.NomuraTakashi, S.SakaguchiShimon. (2003). Control of regulatory T cell development by the transcription factor Foxp3. Science, 299 (5609), 1057–1061.
56. F.Jadidi-Niaragh, A.Mirshafiey (2011). Regulatory T-cell as orchestra leader in immunosuppression process of multiple sclerosis. Immunopharmacol Immunotoxicol, 33 (3), 545–67. doi:10.3109/08923973.2010.513391.
57. J.HelmutJonuleit, E.SchmittEdgar, M.StassenMichael, et al. (2001). Identification and functional characterization of human CD4 CD25 T cells with regulatory properties isolated from peripheral blood. J Exp Med, 193 (11), 1285–1294.
58. K.KennosukeKarube, K.OhshimaKoichi, T.TsuchiyaTakeshi, et al. (2004). Expression of FoxP3, a key molecule in CD4+ CD25+ regulatory T cells, in adult T‐cell leukaemia/lymphoma cells. Br J Haematol, 126 (1), 81–84.
59. K.TsutomuKawabe, T.NakaTetsuji, K.YoshidaKanji, et al. (1994). The immune responses in CD40-deficient mice:impaired immunoglobulin class switching and germinal center formation. Immunity, 1 (3), 167–178.
60. C.A.Keever-Taylor, M.B.Browning, B.D.Johnson, et al. (2007). Rapamycin enriches for CD4+ CD25+ CD27+ Foxp3+ regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. Cytotherapy, 9 (2), 144–157.
61. K.TakumiKumai, K.OikawaKensuke, N.AokiNaoko, et al. (2016). Assessment of the change in cetuximab‐induced antibody‐dependent cellular cytotoxicity activity of natural killer cells by steroid. Head Neck, 38, 410–416.
62. K.Levings Megan, R.SangregorioRomina, M.-G.RoncaroloMaria-Grazia. (2001). Human CD25+ CD4+ T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med, 193 (11), 1295–1302.
63. L.SiripanLimsirichaikul, A.NiimiAtsuko, H.FawcettHeather, et al. (2009). A rapid non-radioactive technique for measurement of repair synthesis in primary human fibroblasts by incorporation of ethynyl deoxyuridine (EdU). Nucleic Acids Res, 37 (4), e31–e31.
64. C.LinChia‐Huey, T.HünigThomas. (2003). Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol, 33 (3), 626–638.
65. W.B.Lindsey, M.W.Lowdell, G.E.Marti, et al. (2007). CD69 expression as an index of T-cell function:assay standardization, validation and use in monitoring immune recovery. Cytotherapy, 9 (2), 123–132.
66. L.WeihongLiu, A.L.PutnamAmy L, Z.Xu-YuZhou, et al. (2006). CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med, 203 (7), 1701–1711.
67. M.W.Lowdell, N.Ray, R.Craston, et al. (1997). The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemia. Bone Marrow Transplantation, 19 (9), 891–897.
68. L.ü.Lanhai, L.ZhangLihong, M.S.M.WaiMaria Sen Mun, et al. (2012). Exocytosis of MTT formazan could exacerbate cell injury. Toxicol Vitro, 26 (4), 636–644.
69. L.A.BruceLyons A, S.J.BlakeStephen J, K.V.DohertyKathleen V. (2013). Flow cytometric analysis of cell division by dilution of CFSE and related dyes. Curr Protoc Cytometry, 9.11. 1-9.11. 12.
70. M.AnlunMa, Q.ShijieQi, Z.WangZiying, et al. (2009). Combined therapy of CD4+ CD25+ regulatory T cells with low-dose sirolimus, but not calcineurin inhibitors, preserves suppressive function of regulatory T cells and prolongs allograft survival in mice. Int Immunopharmacol, 9 (5), 553–563.
71. K.Maghni, O.M.Nicolescu, J.G.Martin (1999). Suitability of cell metabolic colorimetric assays for assessment of CD4+ T cell proliferation:comparison to 5-bromo-2-deoxyuridine (BrdU) ELISA. J Immunol Methods, 223 (2), 185–194.
72. C.Maino Vernon, M.A.SuniMaria A, J.J.RuitenbergJoyce J. (1995). Rapid flow cytometric method for measuring lymphocyte subset activation. Cytometry, 20 (2), 127–133.
73. M.MagisMandapathil, S.LangStephan, E.GorelikElieser, T.L.WhitesideTheresa L. (2009). Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods, 346 (1), 55–63.
74. M.MichaelMardiney, M.R.BrownMargaret R, T.A.FleisherThomas A. (1996). Measurement of T‐cell CD69 expression:A rapid and efficient means to assess mitogen‐or antigen‐induced proliferative capacity in normals. Cytometry, 26 (4), 305–310.
75. M.Ken-ichiMatsuoka, J.KorethJohn, H.T.KimHaesook T, et al. (2013). Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med, 5 (179), 179ra43–179ra43.
76. N.McMurchy Alicia, M.K.LevingsMegan K. (2012). Suppression assays with human T regulatory cells:a technical guide. Eur J Immunol, 42 (1), 27–34.
77. D.Miller Joseph, R.G.van der MostRobbert G, R.S.AkondyRama S, et al. (2008). Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity, 28 (5), 710–722.
78. M.MakotoMiyara, Y.ItoYoshinaga, S.SakaguchiShimon. (2014). TREG-cell therapies for autoimmune rheumatic diseases. Nature Rev Rheumatol, 10, 543–551.
79. M.TimMosmann. (1983). Rapid colorimetric assay for cellular growth and survival:application to proliferation and cytotoxicity assays. J Immunol Methods, 65 (1), 55–63.
80. G.A.Peltz, M.L.Trounstine, K.W.Moore (1988). Cloned and expressed human Fc receptor for IgG mediates anti-CD3-dependent lymphoproliferation. J Immunol, 141 (6), 1891–6.
81. H.Peters Jorieke, F.W.PreijersFrank W, R.WoestenenkRob, et al. (2008). Clinical grade Treg:GMP isolation, improvement of purity by CD127pos depletion, Treg expansion, and Treg cryopreservation. PLoS One, 3, e3161.
82. K.Polansky Julia, K.KretschmerKarsten, J.FreyerJennifer, et al. (2008). DNA methylation controls Foxp3 gene expression. Eur J Immunol, 38 (6), 1654–1663.
83. L.Putnam Amy, T.M.BruskoTodd M, M.R.LeeMichael R, et al. (2009). Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes, 58 (3), 652–662.
84. J.C.Quah Benjamin, R.Parish Christopher (2010). The use of carboxyfluorescein diacetate succinimidyl ester (CFSE) to monitor lymphocyte proliferation. J Visualized Exp, 44, e2259.
85. J.C.Quah Benjamin, D.K.WijesundaraDanushka K, C.RanasingheCharani, C.R.ParishChristopher R. (2014). The use of fluorescent target arrays for assessment of T cell responses in vivo. JoVE, 88, e51627.
86. R.AlexRabinovitch, W.L.Suarez-PinzonWilma L, S.A.M.JamesShapiro AM, et al. (2002). Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes, 51 (3), 638–645.
87. T.L.Riss, R.A.Moravec, A.L.Niles, et al. (2004). Cell Viability Assays. In Assay Guidance Manual, edited by G.S.Sittampalam, N.P.Coussens, H.Nelson, M.Arkin, D.Auld, C.Austin, B.Bejcek, M.Glicksman, J.Inglese, P.W.Iversen, Z.Li, J.McGee, O.McManus, L.Minor, A.Napper, J.M.Peltier, T.Riss, O.J.Trask, Jr. and J.Weidner. Bethesda (MD):Eli Lilly & Company and the National Center for Advancing Translational Sciences.
88. R.OlafRoetzschke, K.FalkKirsten, M.KleinewietfeldMarkus. (2015). Method and kit for rapid isolation of human Foxp3+ Treg cells. Google Patents.
89. J.Ruitenberg Joyce, C.BoyceChristopher, R.HingoraniRavi, et al. (2011). Rapid assessment of in vitro expanded human regulatory T cell function. J Immunol Methods, 372 (1), 95–106.
90. S.PervinderSagoo, G.LombardiGiovanna, R.I.LechlerRobert I. (2008). Regulatory T cells as therapeutic cells. Current Opinion Organ Transplantation, 13 (6), 645–653.
91. S.Sakaguchi, N.Sakaguchi, M.Asano, et al. (1995a). Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 155 (3), 1151–64.
92. S.Sakaguchi, T.Yamaguchi, T.Nomura, M.Ono (2008). Regulatory T cells and immune tolerance. Cell, 133 (5), 775–87. doi:10.1016/j.cell.2008.05.009.
93. S.ShimonSakaguchi. (2008). Regulatory T cells in the past and for the future. Eur J Immunol, 38 (4), 901–937.
94. S.ShimonSakaguchi, M.MiyaraMakoto, C.M.CostantinoCristina M, D.A.HaflerDavid A. (2010). FOXP3+ regulatory T cells in the human immune system. Nature Rev Immunol, 10 (7), 490–500.
95. S.ShimonSakaguchi, N.SakaguchiNoriko, M.AsanoMasanao, et al. (1995b). Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 155 (3), 1151–1164.
96. S.ShimonSakaguchi, D.A.A.VignaliDario AA, A.Y.RudenskyAlexander Y., et al. (2013a). The plasticity and stability of regulatory T cells. Nat Rev Immunol, 13 (6), 461–467. doi:10.1038/nri3464.
97. S.ShimonSakaguchi, D.A.A.VignaliDario AA, A.Y.RudenskyAlexander Y, et al. (2013b). The plasticity and stability of regulatory T cells. Nat Rev Immunol, 13 (6), 461–467.
98. S.SaskiaSantegoets, M.J.P.WeltersMarij JP, V.D.B.Sjoerd Hvan der Burg. (2014). Detection and functional assessment of regulatory T cells in clinical samples. J Immunother Cancer, 2 (Suppl 3), P154.
99. S.StephanSauer, L.BrunoLudovica, A.HertweckArnulf, et al. (2008). T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci, 105 (22), 7797–7802.
100. S.AngelikaSchmidt, N.OberleNina, P.H.KrammerPeter H. (2012). Molecular mechanisms of treg-mediated T cell suppression. Frontiers in Immunol, 3, 46.
101. S.ThomasScholzen, J.GerdesJohannes. (2000). The Ki-67 protein:from the known and the unknown. J Cell Physiol, 182 (3), 311–322.
102. S.NabilaSeddiki, B.Santner-NananBrigitte, J.MartinsonJeff, et al. (2006). Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med, 203 (7), 1693–1700.
103. V.Serreze David, H.D.ChapmanHarold D, D.S.VarnumDon S, et al. (1996). B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes:analysis of a new speed congenic stock of NOD. Ig mu null mice. J Exp Med, 184 (5), 2049–2053.
104. M.Shevach Ethan (2002). CD4+ CD25+ suppressor T cells:more questions than answers. Nat Rev Immunol, 2 (6), 389–400.
105. M.Shevach Ethan (2009). Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity, 30 (5), 636–645.
106. E.Simms Patricia, T.M.EllisThomas M. (1996). Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly-and oligoclonal lymphocyte activation. Clin Diagn Lab Immunol, 3 (3), 301–304.
107. K.Singh, N.Kozyr, L.Stempora, et al. (2012). Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus. Am J Transplantation, 12 (6), 1441–1457.
108. S.LauraStrauss, M.CzystowskaMalgorzata, M.SzajnikMarta, et al. (2009). Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One, 4 (6), e5994.
109. S.LauraStrauss, T.L.WhitesideTheresa L, A.KnightsAshley, et al. (2007). Selective survival of naturally occurring human CD4+ CD25+ Foxp3+ regulatory T cells cultured with rapamycin. J Immunol, 178 (1), 320–329.
110. S.MurielStubbe, N.VanderheydeNathalie, M.GoldmanMichel, A.MarchantArnaud. (2006). Antigen-specific central memory CD4+ T lymphocytes produce multiple cytokines and proliferate in vivo in humans. J Immunol, 177 (11), 8185–8190.
111. T.SatoshiTanaka, S.MaedaShinji, M.HashimotoMotomu, et al. (2010). Graded attenuation of TCR signaling elicits distinct autoimmune diseases by altering thymic T cell selection and regulatory T cell function. J Immunol, 185 (4), 2295–2305.
112. T.QizhiTang, J.Y.AdamsJason Y, C.PenarandaCristina, et al. (2008). Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity, 28 (5), 687–697.
113. T.QizhiTang, K.J.HenriksenKammi J, B.MingyingBi, et al. (2004). In vitro–expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med, 199 (11), 1455–1465.
114. T.RanTao, E.F.de ZoetenEdwin F, E.ÖzkaynakEngin, et al. (2007). Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med, 13 (11), 1299–1307.
115. T.RobertoTesti, D.D’AmbrosioDaniele, R.De MariaRuggero, A.SantoniAngela. (1994). The CD69 receptor:a multipurpose cell-surface trigger for hematopoietic cells. Immunol Today, 15 (10), 479–483.
116. D.Q.Tran, H.Ramsey, E.M.Shevach (2007). Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood, 110 (8), 2983–90. doi:10.1182/blood-2007-06-094656.
117. Q.Tran Dat (2013). In vitro suppression assay for functional assessment of human regulatory T cells. Immune Homeostasis:Methods Protoc, 199–212.
118. T.PiotrTrzonkowski, M.BieniaszewskaMaria, J.JuścińskaJolanta, et al. (2009). First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+ CD25+ CD127− T regulatory cells. Clin Immunol, 133 (1):22–26.
119. N.Ukena Sya, M.HöptingMatthias, S.VelagaSarvari, et al. (2011). Isolation strategies of regulatory T cells for clinical trials:phenotype, function, stability, and expansion capacity. Exp Hematol, 39 (12), 1152–1160.
120. C.van KootenCees, J.BanchereauJacques. (2000). CD40-CD40 ligand. J Leukocyte Biol, 67 (1), 2–17.
121. A.van Tonder, A.M.Joubert, A.D.Cromarty (2015a). Limitations of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay when compared to three commonly used cell enumeration assays. BMC Res Notes, 8, 47. doi:10.1186/s13104-015-1000-8.
122. A.van TonderAlet, A.M.JoubertAnnie M, A.D.CromartyA Duncan. (2015b). Limitations of the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay when compared to three commonly used cell enumeration assays. BMC Res Notes, 8 (1), 47.
123. V.-A.ElisaVega-Avila, M.K.PugsleyMichael K. (2011). An overview of colorimetric assay methods used to assess survival or proliferation of mammalian cells. Proc West Pharmacol Soc, 54, e4.
124. W.UteWagner, E.BurkhardtEberhard, K.FailingKlaus. (1999). Evaluation of canine lymphocyte proliferation:comparison of three different colorimetric methods with the 3H-thymidine incorporation assay. Vet Immunol Immunopathol, 70 (3–4), 151–159. doi: http://dx.doi.org/10.1016/S0165-2427(99)00041-0.
125. W.KajsaWing, S.SakaguchiShimon. (2010). Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol, 11 (1), 7–13.
126. Y.HangYan, C.-G.DingChen-Guang, P.-X.TianPu-Xun, et al. (2009). Magnetic cell sorting and flow cytometry sorting methods for the isolation and function analysis of mouse CD4+ CD25+ Treg cells. J Zhejiang Univ Sci B, 10 (12), 928–932.
127. J.Yellin Michael, K.SippelKimberly, G.InghiramiGiorgio, et al. (1994). CD40 molecules induce down-modulation and endocytosis of T cell surface T cell-B cell activating molecule/CD40-L. Potential role in regulating helper effector function. J Immunol, 152 (2), 598–608.
128. Z.RobertZeiser, D.B.Leveson-GowerDennis B, E.A.ZambrickiElizabeth A, et al. (2008). Differential impact of mammalian target of rapamycin inhibition on CD4+ CD25+ Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood, 111 (1), 453–462.